explore -WSS

explore

author：comprehensive 2025-10-01 17:20:26 - browse：8115

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Do more moles mean more problems? Not so, says new study

leisure time

WSS

Scientists successfully use ultrasound imaging to map brain activity

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Average age of first period drops to 11.9 years, study shows

Alabama frozen embryo ruling has major implications for IVF clinics

6 phony surgeries that take placebo to the extreme

knowledge

explore

explore

Apple is now the first public company to be valued at $3 trillion

AI used to predict Covid

United colonoscopy coverage change 'may cost lives,' doctors say

NIH study of ME/CFS points to clear biological hallmarks

Peter Hotez and the public health issue of online harassment

Alabama frozen embryo ruling has major implications for IVF clinics

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Obesity drugs seen as possible treatment for liver disease MASH

Apple is now the first public company to be valued at $3 trillion

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Wikipedia

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Alabama IVF ruling threatens families facing fatal genetic disease

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

First Opinion Podcast: What happens when kids become caregivers?

Health insurers say they are turning to AI to cut costs, improve care

hotspot

leisure time

leisure time

hotspot